Tretinoin 0.05% | Triamcinolone 0.1% | Hydroquinone 10%

Applied topically once nightly to affected hyperpigmented areas only, on clean, dry skin. Apply a thin layer with a fingertip; avoid the periorbital area (triamcinolone-associated glaucoma risk), nostrils, lips, and mucous membranes. Apply broad-spectrum SPF 30+ sunscreen every morning without exception. Do not use under occlusion, as occlusion significantly increases systemic absorption of both triamcinolone and hydroquinone.

Apply a thin layer once nightly to affected areas only. Given the high potency of all three components, the prescribing clinician typically limits continuous use to 6–12 weeks, followed by reassessment and transition to lower-strength maintenance therapy. This formulation is not appropriate for prolonged unsupervised use. All dosing decisions are at the prescriber's discretion.

• Tretinoin (0.05%): Binds RAR-α, RAR-β, RAR-γ and RXR nuclear receptors → drives epidermal renewal and keratinocyte differentiation → disperses melanin granules, inhibits melanocyte-keratinocyte melanosome transfer, induces procollagen I/III synthesis, and increases dermal penetration of hydroquinone through stratum corneum thinning.
• Triamcinolone (0.1%): Fluorinated corticosteroid that binds intracellular glucocorticoid receptors → induces lipocortin-1 → inhibits phospholipase A2 → reduces arachidonic acid release → blocks prostaglandin (PGE2) synthesis. PGE2 is a potent melanocyte activator; its suppression interrupts the inflammatory hyperpigmentation cycle. Triamcinolone also inhibits NF-κB, reduces pro-inflammatory cytokine production, and suppresses retinoid- and hydroquinone-induced erythema.
• Hydroquinone (10%): Competitive inhibitor of tyrosinase at the L-DOPA oxidation step; at 10%, exerts both competitive enzyme inhibition and direct melanocytotoxic effects through oxidative stress on melanocytes. Provides faster and deeper depigmentation than standard 4–6% concentrations for severe melasma.

This high-potency triplet formulation is reserved for severe, refractory melasma (particularly Fitzpatrick phototypes IV–VI), extensive PIH, or cases that have failed standard Kligman formula therapy (tretinoin + hydroquinone 4–6% + low-potency corticosteroid). Because all three components carry significant risk profiles at these concentrations, prescriber-directed use with close follow-up is mandatory.

Monitoring considerations:

• Clinical evaluation every 4–6 weeks during treatment to assess response and detect early adverse effects
• Monitor for ochronosis (paradoxical blue-black discoloration): discontinue immediately if suspected; risk is highest with prolonged 10% hydroquinone use
• Monitor for triamcinolone-related skin changes: atrophy, telangiectasias, striae, perioral dermatitis, acneiform eruption
• Assess intraocular pressure if applied in the periorbital region; triamcinolone can increase IOP
• Monitor for HPA axis suppression with large surface area or prolonged use of triamcinolone
• Reinforce mandatory daily broad-spectrum sunscreen

Contraindications:

• Hypersensitivity to any component
• Periorbital application (corticosteroid-induced glaucoma risk)
• Active skin infection at application site
• Pregnancy (first trimester especially; avoid all components; minimize hydroquinone and corticosteroid throughout pregnancy)
• Children (significant risk of systemic corticosteroid absorption)

Warnings & Precautions:

• Ochronosis: highest risk with 10% hydroquinone; limit continuous use strictly to 6–12 weeks; monitor all patients
• HPA axis suppression: triamcinolone 0.1% on facial skin carries meaningful systemic absorption; restrict to small surface areas, short treatment durations, no occlusion
• Skin atrophy, telangiectasias, striae: triamcinolone on facial/flexural skin—monitor closely and discontinue if changes appear
• Glaucoma and increased intraocular pressure: avoid periorbital area entirely with triamcinolone
• Photosensitivity: all three components increase UV sensitivity; mandatory daily sunscreen is non-negotiable
• Systemic absorption of hydroquinone: avoid large surface areas, broken skin, and occlusion

Drug Interactions:

• Other topical retinoids: additive irritation if used concurrently
• Systemic corticosteroids: additive HPA suppression risk
• Photosensitizing drugs: additive photosensitivity risk with tretinoin

Common Side Effects: Erythema, peeling, dryness, burning/stinging (tretinoin); skin atrophy, telangiectasias, striae, acneiform eruption (triamcinolone); ochronosis with prolonged high-dose hydroquinone exposure.

Store at room temperature (15–25°C) in opaque, sealed packaging protected from light and air. Hydroquinone oxidizes and turns brown upon air and light exposure; do not use if the preparation appears discolored. Do not freeze. Use within the beyond-use date assigned by Genesis Compounding per 503A regulatory requirements.

Why is 10% hydroquinone used in this formula?

10% hydroquinone is a high concentration reserved for severe or refractory hyperpigmentation that has not adequately responded to standard 4–6% formulations. It is used only under close prescriber supervision for limited treatment courses, due to the elevated risk of ochronosis with prolonged use.

Is triamcinolone stronger than hydrocortisone?

Yes. Triamcinolone acetonide 0.1% is a fluorinated moderate-to-high-potency corticosteroid, significantly more potent than hydrocortisone 2.5%. It provides stronger anti-inflammatory suppression of melanocyte activation, but carries greater risks of skin atrophy, glaucoma, and HPA axis suppression with improper use.

How long can I safely use this formulation?

Due to the high potency of all three ingredients, continuous use is typically limited to 6–12 weeks under close prescriber supervision, followed by a rest period or transition to a lower-strength maintenance regimen. Your prescriber will determine the appropriate treatment schedule.

What is ochronosis and why is it a concern at 10% hydroquinone?

Ochronosis is a paradoxical blue-black discoloration of skin that can develop with prolonged or high-dose hydroquinone use, most commonly in patients with darker skin phototypes. The risk is highest with concentrations above 4% used for extended periods. Report any unusual darkening or bluish discoloration immediately to your prescriber.

Is this FDA-approved?

This is a 503A compounded preparation by Genesis Compounding, prepared under a valid prescriber order for a specific patient. No commercially available FDA-approved product contains all three agents at these concentrations; this formulation is patient-specific and not FDA-approved as a compounded drug product.